Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psoriasis
Biotech
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials.
James Waldron
Mar 10, 2025 7:30am
BMS backs out of Dupixent fight, axing asset despite phase 3 win
Feb 7, 2025 6:26am
AbbVie acquires oral peptide biotech Nimble for $200M
Dec 13, 2024 10:38am
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
Nov 19, 2024 11:44am
Lilly changes lead psoriasis program from $2.4B Dice buyout
Oct 30, 2024 10:00am
Awaiting regulator verdict, Innovent posts latest psoriasis win
Oct 29, 2024 9:50am
